5mg/vial GHRP-2 (human growth) / E-mail:zmq3@ycphar.com

• Product Name5mg/vial GHRP-2 (human growth) / E-mail:zmq3@ycphar.com
  CAS No.87616-84-0
  Purity99%
  Min Quantity5Metric Tons
  Price1~5
• View Contact Detail

• 
  Molecular Structure

Detailed Description

5mg/vial GHRP-2 (human growth) / E-mail:zmq3@ycphar.com

Basic info.

Model NO.:GHRP-2
Alias:Ghrp-2
Model NO.:87616-84-0
Package:100% Safe Ways
Character:White Powder
Delivery Time:Within 24 Hours After Payment
Shipping Ways:EMS, TNT, FedEx, DHL, by Air, etc
Payment:Western Union, Moneygram, Bank Transfer
Export Markets:Global

Additional info.

Trademark:Saichuang
Packing:Safe Ways 100% Pass Customs
Standard:GMP, ISO, UP, SP,
Origin:Guangdong, China
Production Capacity:6000kg/Month

Product Description

5mg/vial GHRP-2

Product descroption:

GHRP-2 is a synthetic ghrelin analogue. Like ghrelin, it stimulates release of endogenous growth hormone from somatotropes in the anterior pituitary; also like ghrelin, it is synergistic with endogenous growth hormone releasing-hormone (GHRH) as well as with synthetic GHRH analogues such as Sermorelin or GRF(1-29). Whereas GHRP-2 and other ghrelin analogues increase the number of somatotropes involved in the GH pulse by inhibiting somatostatin, GHRH increases the pulse amplitude per pituitary cell or somatotrope by other means. Unlike ghrelin, GHRP-2 is not lipogenic meaning it does not induce fat storage. While ghrelin has a very important role in hunger, GHRP-2 as an analog of ghrelin does not increase appetite significantly. GHRP-2 is synergistic with GHRH due to secondary actions on hypothalamic neurons. The quantity of GH released by a living mammal to which GHRP-2 and GHRH are administered exceeds the combined release of each compound when measured when taken alone.


how to use:

In humans, a dose of 1mcg/kg (100mg for a 100kg male) of GHRP-2 when combined with a GHRH of equal dosage creates a three-hour pulse of GH that is double the amplitude of an 8 IU synthetic (e.coli derived) growth hormone dose. IV, intramuscular and subcutaneous routes lead to different onset times but roughly similar peaks and declines.